Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing
The journal Nature Medicine has retracted a high-profile study examining the impact of daily treatment timing on lung cancer immunotherapy survival rates.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Nature Medicine has officially retracted a scientific paper that previously suggested a link between the timing of PD-1 immunotherapy administration and survival outcomes in lung cancer patients. Coverage from outlets including Nature, MedPage Today, Oncodaily, 747 Live, Endpoints News, and Fierce Pharma reports on the retraction.
These sources emphasize that the study was provocative and sparked significant debate within the oncology community regarding chronotherapy. Observers are now focused on the broader implications of this retraction within the scientific and policy landscapes.
Reporting notes that the development may influence ongoing discussions regarding research integrity and international scientific collaboration.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated just now.
Quick answers
What was the core claim of the retracted study?
The study suggested that the time of day a PD-1 immunotherapy drug was administered influenced survival outcomes for lung cancer patients.
Which journal published and retracted the study?
Nature Medicine.
What are the potential future impacts noted in coverage?
Coverage suggests the retraction may influence scientific scrutiny and could be utilized in discussions regarding international research relations.
Coverage (5)
- Nature Retracts Cancer Study Suggesting Treatment Is Better Earlier in the Day MedPage Today · 1d ago
- Paolo Tarantino: Nature Medicine Retracts Debated Study on Early Morning Immunotherapy Benefits Oncodaily · 1d ago
- Nature Medicine retracts Chinese lung cancer immunotherapy timing study 747 Live · 1d ago
- Retraction of high-profile paper on cancer drug timing could hand ammo to China hawks Endpoints News · 1d ago
- Nature retracts provocative PD-1 study that tied lung cancer survival to treatment timing Fierce Pharma · 1d ago
Topics
Related trends
GABA Immune Pathway Drives Female Brain Cancer Growth
Researchers have identified a sex-specific GABA immune pathway that promotes glioblastoma progression in female subjects.
A molecule called MHC I was understood for decades as the thing that lets the immune system recognize cancer, until researchers found the immune system attacks hardest exactly when cancer switches it off
Cancer’s immune-evasion trick just got exposed—what it means for treatments is unclear yet
As cancer death rates plunge, clear disparities remain, new report says
A new AACR report highlights that while U.S. cancer death rates have dropped significantly since 1991, severe geographic and socioeconomic disparities persist.
A blood test that screens for multiple types of cancer? It may be available soon
Advancements in multi-cancer early detection blood tests are sparking debate over their readiness for widespread clinical use.
3 People Have Gotten Cancer-Detecting Implants in Their Brains
A US startup has implanted experimental cancer-detection devices in three patients’ brains—marking a potential leap in early tumor diagnosis.
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer’s experimental lung cancer drug sigvotatug vedotin has failed to meet its primary objective in a late-stage clinical trial.